AB Science présentera son programme de développement dans la Sclérose Latérale Amyotrophique (SLA) lors de l’édition 2022 du ALS Drug Development Summit
07 févr. 2022 12h12 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA SON PROGRAMME DE DÉVELOPPEMENT DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) LORS DE L’ÉDITION 2022 DU ALS DRUG DEVELOPMENT SUMMIT Paris, 7 février 2022,...
AB Science reçoit l’autorisation de la FDA de reprendre le recrutement des patients dans l'étude confirmatoire de phase 3 du masitinib (AB19001) chez les patients atteints de SLA
18 nov. 2021 14h40 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT L'AUTORISATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE DE REPRENDRE LE RECRUTEMENT DE PATIENTS DANS L'ÉTUDE DE PHASE 3 DU MASITINIB DANS LA...
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
18 nov. 2021 14h40 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) ...
Global Neurological Therapies Market Research Report 2021: Competitive Landscape and Pipeline Analysis Focusing Specifically on Therapeutic Interventions for Neurodegenerative Diseases
15 nov. 2021 07h08 HE
|
Research and Markets
Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Global Neurological Therapies Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research has identified novel...
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
06 oct. 2021 08h00 HE
|
Sunshine Biopharma Inc.
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
AB Science annonce aujourd'hui qu'un résumé des résultats de survie à long terme du masitinib dans SLA a été sélectionné pour une présentation lors de la réunion annuelle de la Société Espagnole de Neurologie
20 sept. 2021 13h15 HE
|
AB Science
COMMUNIQUE DE PRESSE LES RESULTATS DE SURVIE A LONG TERME DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE ONT ETE SELECTIONNES POUR UNE ALLOCUTION EN PLENIERE EN TANT QUE « PRESENTATION ORALE DE...
AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
20 sept. 2021 13h15 HE
|
AB Science
PRESS RELEASE RESULTS FROM LONG-TERM SURVIVAL ANALYSIS OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS SELECTED FOR PLENARY SPEECH AS “STAR ORAL COMMUNICATION” AT THE SPANISH SOCIETY OF NEUROLOGY...
PathMaker Neurosystems Announces Receipt of NIH Grant For Application of its Non-Invasive Neuromodulation Technology to Amyotrophic Lateral Sclerosis (ALS)
20 sept. 2021 13h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
05 sept. 2021 13h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
02 sept. 2021 11h59 HE
|
AB Science
PRESS RELEASE AB SCIENCE TO PRESENT LATEST CLINICAL DATA ON LONG-TERM SURVIVAL ANALYSES IN AMYOTROPHIC LATERAL SCLEROSIS AT THE 2021 INTERNATIONAL SYMPOSIUM ON ALS/MND Paris, 2 September, 2021, 6pm...